Tag Archives: N8GP

FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A

FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A Print this page Bagsværd, Denmark, 19 February 2019 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for Esperoct for the treatment of adults and children with hemophilia A. Esperoct is the brand name for… Read More »